cell transplantation

[Leukemia & Lymphoma] The authors investigated the prognostic significance of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) in t(8;21) acute myeloid leukemia (AML). A total of 47 t(8;21) AML patients were tested for TIM-3 expression by multi-parameter flow cytometry at diagnosis.

[Blood] This phase I-II study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). BV and Nivo with staggered or concurrent dosing were active and well tolerated when used as first salvage therapy in patients with r/r cHL.

[Medexus Pharmaceuticals, Inc.] Medexus Pharmaceuticals, Inc. announced that is has completed enrollment in its Phase IV Clinical Trial of IXINITY®, targeting label expansion for pediatric hemophilia B patients.

[IN8bio, Inc.] IN8bio, Inc. announced completion of dosing of the first patient cohort in a Phase I clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant.

[Nature Communications] Scientists showed that human T cells engineered to express an mLPA-specific TCR, targeted diverse CD1c-expressing leukemia blasts in vitro and significantly delayed the progression of three models of leukemia xenograft in NSG mice, an effect that was boosted by mLPA-cellular immunization.

[Bone Marrow Transplantation] The association between hematopoietic stem-cell transplantation and early- and late-onset cardiotoxicity remains controversial as these cardiac complications, including acute heart failure and arrhythmia, such as atrial fibrillation, can occasionally be lethal.